Gastrointestinal Cancers
ASCO 2022: Dostarlimab-gxly in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
You're currently viewing OncGenius as a guest. To save your results, create an account or log in.
Advertisement
Advertisement
ASCO 2022: Dostarlimab-gxly in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
ASCO 2022: Nimotuzumab Plus Gemcitabine for KRAS Wild-Type Pancreatic Cancer
ASCO 2022: Panitumumab Plus mFOLFOX6 for Certain Patients With Metastatic Colorectal Cancer
ASCO 2022: Using ctDNA to Guide Adjuvant Chemotherapy in Colon Cancer
MSI-H/dMMR Advanced Colorectal Cancer: Pembrolizumab vs Chemotherapy
Pembrolizumab/Trametinib vs Gemcitabine in Addition to SBRT for Pancreatic Cancer
Immunotherapy Doublet in Patients With MSI-H/dMMR Metastatic Colorectal Cancer
Combination Anti–PD-L1 and Anti–CTLA-4 Immunotherapy in Advanced Liver Cancer
TOPAZ-1 Trial: Durvalumab and Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Treatment Options for Patients With GIST Following Disease Progression